Episode
Breast Cancer — Proceedings from a Session Held in Conjunction with the 2026 ASCO Annual Meeting on the Use of Oral SERDs and Agents Targeting the PI3K/AKT/mTOR Pathway
- Podcast
- Breast Cancer Update
- Published
- Jul 25, 2026
- Duration seconds
- 7096
- Processing state
not_requested
Actions
POST https://stenobird.com/v1/public/podcasts/breast-cancer-update-757579/episodes/breast-cancer-proceedings-from-a-session-held-in-conjunction-with-the-2026-asco-annual-meeting-on-the-use-of-oral-serds-and-agents-targeting-the-pi3k-akt-mtor-pathway/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/breast-cancer-update-757579/breast-cancer-proceedings-from-a-session-held-in-conjunction-with-the-2026-asco-annual-meeting-on-the-use-of-oral-serds-and-agents-targeting-the-pi3k-akt-mtor-pathway.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
Featuring perspectives from Dr Sara A Hurvitz, Dr Erica Mayer, Dr Joyce O’Shaughnessy, Dr Sara M Tolaney and Dr Nicholas Turner, moderated by Dr Tolaney, including the following topics: Introduction (0:00) Current and Future Roles of Agents Targeting the PI3K/AKT/mTOR Pathway and Oral Selective Estrogen Receptor Degraders (SERDs) in First-Line Therapy for HR-Positive, HER2-Negative Metastatic Breast Cancer (mBC) — Dr Turner (2:35) Role of Oral SERD Monotherapy in the Treatment of Progressive HR-Positive, HER2-Negative mBC — Dr O’Shaughnessy (25:23) Potential Use of Oral SERD-Containing Combination Regimens in Managing Progressive HR-Positive, HER2-Negative mBC — Dr Mayer (46:29) Clinical Utility of Agents Targeting the PI3K/AKT/mTOR Pathway for Patients with Progressive HR-Positive, HER2-Negative mBC — Dr Hurvitz (1:07:06) Potential Use of Oral SERDs for HR-Positive, HER2-Negative Localized Breast Cancer — Dr Tolaney (1:38:17) CME information and select publications